Obermatt
See Similar Stocks →

AnaptysBio

NSQ:ANAB · US0327241065
BiotechnologySmall

360

44
EV / EBIT31
Price / Owner Earnings95
Owner Earnings Yield1
Dividend Yield1
Price/Sales20
EV / Gross Profit32
Price/Book3
Return on Capital90
Cash Return on Capital9
Return on Equity13
EBIT Margin84
Gross Profitability79
Accruals97
Owner Earnings Margin75
Sales growth9
Profit growth65
Reinvestment88
Price momentum94
Debt load12
Refinancing46
Debt Payback1
Liquidity56
Analyst ratings59
Opinion Changes88
Price Target Upside46
Market mood77
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

AnaptysBio clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2005
Employees116
Websiteanaptysbio.com
ISINUS0327241065
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyRheumatologyInflammationChronic DiseasesOncologyDermatologyBiotechnologyHealth CareTherapeutics

Description

AnaptysBio, Inc. (Anaptys), a clinical-stage biotechnology company, focuses on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Clinical-Stage Pipeline The company’s clinical-stage pipeline consists of rosnili…

Analysis

Middle-of-the-road

AnaptysBio, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 7/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
47
2026

All-time high

84

Mar 2026

All-time low

47

Jun 2026

Average rank

66

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
20
—
—
—
Price/Earnings
8
—
—
—
Price/Book
3
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
1
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare AnaptysBio with its peers
Equillium
NAQ:EQ
56
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Eledon Pharmaceuticals
NAQ:ELDN
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Trevi Therapeutics
NMQ:TRVI
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Structure Therapeutics
NMQ:GPCR
67
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Nektar
NAQ:NKTR
4
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Relmada Therapeutics
NAQ:RLMD
—
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →